Answers are grounded in this paper and cite their sources.
A recent report from the American College of Physicians (ACP) should cause a paradigm change for the treatment of diabeticpatients.1 The main purpose of diabetes therapy is the prevention of complications.2 The endpoint of many clinical trials is to lowerblood glucose levels, but intensive treatments aimed at lowering the HbA1c to less than 6.5% are often accompanied by hypoglycemiaas a side effect. At the same time, intensive regimens have not shown a reduction of cardiovascular complications in the longterm.3-7 For example, the action to control cardiovascular risk in diabetes (ACCORD) trial was prematurely discontinued, followingthe observation of an increase in overall mortality, cardiovascular- related deaths, and severe hypoglycemic events.3 The action in diabetes and vascular disease; preterAx and diamicroN-MR controlled evaluation (ADVANCE) study also failed to show a statisticallysignificant clinical benefit, while more adverse effects were seen among those who achieved a median HbA1c level of 6.4%.4 More intensive treatments with tight glycemic control targets are more costly and associated with increased patient burdens. OnlyHollan et al8 reported a long-term benefit with intensive therapy in the United Kingdom prospective diabetes study (UKPDS) after10 years of intervention.
No takes yet. Share an insight, caveat, or question.
Shaw Watanabe (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: